The SURMOUNT-MMO trial is the first dedicated cardiovascular outcomes study for Tirzepatide. Early results suggest the dual GIP/GLP-1 agonist may reduce major adverse cardiac events in patients with obesity.
View the full PeptX research peptide catalogue, or browse Retatrutide, Tirzepatide, Semaglutide, BPC-157, TB-500 and GHK-Cu.